[Valve-in-valve transcatheter mitral valve replacement with SAPIEN 3 valve for bioprosthetic mitral valve failure: one-year outcomes in 26 patients].

ABSTRACT:

Objectives

To evaluate the one-year outcomes of valve-in-valve transcatheter mitral valve replacement (ViV-TMVR) using SAPIEN 3 valve for treating mitral bioprosthetic valve failure.

Methods

A retrospective analysis was conducted on 26 patients with mitral bioprosthetic valve failure who underwent ViV-TMVR at West China Hospital, Sichuan University, between November 2022 and July 2024. The age of patients was 71.5 (64.5, 74.5) years, and 69.2% were female. Bioprosthetic valve failure occurred at (9.7±3.7) years after initial surgical implantation, with the most common failure mode being mixed stenosis and regurgitation (53.8%). The SAPIEN 3 valve was implanted via either a transseptal or transapical approach. Echocardiography was performed preoperatively, immediately post-pr

SUBMITTER: Ran Z 

PROVIDER: S-EPMC12571703 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature